Lantheus Holdings (LNTH) Income from Continuing Operations (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Income from Continuing Operations came in at 118417000.0 in Q1 2026, up 62.34% year-on-year from 72945000.0 in Q1 2025, and down 16.68% on a QoQ basis from 142118000.0 in Q4 2025.
Lantheus Holdings (LNTH) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Income from Continuing Operations data on file, last reported at 118417000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 62.34% year-over-year to 118417000.0 in Q1 2026; TTM through Mar 2026 was 367061000.0, a 566.01% increase from a year earlier, with the FY2025 full-year figure at 321589000.0, up 1657.63% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 118417000.0, down from 142118000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for LNTH reached as high as 142118000.0 in Q4 2025 and fell as low as 344878000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 45416000.0 across 5 years, with a median of 72945000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 4769.26% in 2024 and fell as far as 440.24% in 2024.
- Year by year, Income from Continuing Operations stood at 119185000.0 in 2022, then surged by 185.05% to 101364000.0 in 2023, then tumbled by 440.24% to 344878000.0 in 2024, then soared by 141.21% to 142118000.0 in 2025, then declined by 16.68% to 118417000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 118417000.0 in Q1 2026, 142118000.0 in Q4 2025, and 27771000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 118.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.42 Mn |
| Dec 31, 2025 | 142.12 Mn |
| Sep 30, 2025 | 27.77 Mn |
| Jun 30, 2025 | 78.76 Mn |
| Mar 31, 2025 | 72.95 Mn |
| Dec 31, 2024 | -344.88 Mn |
| Sep 30, 2024 | 131.09 Mn |
| Jun 30, 2024 | 62.07 Mn |
| Mar 31, 2024 | 131.07 Mn |
| Dec 31, 2023 | 101.36 Mn |
| Sep 30, 2023 | 131.96 Mn |
| Jun 30, 2023 | 94.13 Mn |
| Mar 31, 2023 | -2.81 Mn |
| Dec 31, 2022 | -119.19 Mn |
| Sep 30, 2022 | 61.23 Mn |
| Jun 30, 2022 | 43.06 Mn |
| Mar 31, 2022 | 42.96 Mn |
| Dec 31, 2021 | -40.22 Mn |
| Sep 30, 2021 | -13.42 Mn |
| Jun 30, 2021 | -26.66 Mn |